Paper Details
- Home
- Paper Details
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Author: AkardLuke, CaldemeyerLauren, DuganMichael, EdwardsJohn
Original Abstract of the Article :
Most patients with chronic myeloid leukemia have deep and durable responses when treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs). Imatinib (the first approved TKI), nilotinib, and dasatinib are used in newly diagnosed, relapsed or intolerant patients, while bosutinib and ponatinib are used o...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1007/s11899-016-0309-2
データ提供:米国国立医学図書館(NLM)
Chronic Myeloid Leukemia: Navigating the Long-Term Landscape
The field of [oncology and hematology] is constantly evolving, with new treatments and therapies emerging to combat various cancers. This research explores the long-term implications of tyrosine kinase inhibitors (TKIs), a class of drugs used to treat chronic myeloid leukemia (CML). The study focuses on the potential side effects of these drugs, particularly their impact on the heart and lungs, and the need for careful monitoring and management of these adverse effects.
The Balancing Act of Treatment
While TKIs have been successful in controlling CML, their long-term effects are becoming increasingly apparent. The study reveals that approximately 10% of patients experience intolerance to their initial TKI, and an increasing number are developing long-term side effects. This highlights the challenge of finding the right balance between controlling the disease and minimizing the impact of treatment on quality of life. It's like navigating a vast desert, where the path to recovery can sometimes lead to unforeseen challenges.
Patient-Centered Care: A Critical Focus
This study underscores the importance of patient-centered care and a holistic approach to managing CML. It highlights the need for close monitoring of long-term toxicities and proactive management of potential side effects. It's a reminder that the journey to recovery is not always linear, and requires ongoing collaboration between patients and their healthcare providers. Think of it as a shared journey through the desert, where careful planning and ongoing support are crucial for reaching the oasis of health.
Dr.Camel's Conclusion
This research provides valuable insights into the long-term implications of TKI therapy for CML. It emphasizes the need for ongoing research and careful monitoring of patients to optimize treatment strategies and minimize adverse effects. It's a reminder that the journey to recovery is not always a straight path through the desert, but a series of interconnected steps, requiring careful navigation and unwavering support.
Date :
- Date Completed 2017-08-24
- Date Revised 2018-11-13
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.